Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells
June 12, 2017 updated by: Todd C. Villines, Walter Reed National Military Medical Center
The HEART BREAK Study: Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells
Purpose
- To investigate the effects of cardiac imaging radiation on the induction of DNA double-strand breaks by enumerating gamma-H2AX foci in blood lymphocytes and plucked hair follicle cells.
- To estimate whether the use of breast shields in cardiac computed tomographic angiography (CCTA) limits the effective radiation exposure of breast tissue.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the study is to analyze blood and hair samples from patients undergoing cardiac imaging to estimate radiation exposure levels as well as their biological effects (i.e. to determine the degree of genotoxicity by measuring the amounts of DNA double-strand breaks).
The secondary objective is to investigate whether the use of in-plane breast shielding in female patients undergoing CT angiography (CCTA) limits the radiation exposure of breast tissue and subsequent DNA damage in blood lymphocytes and hair follicle cells.
Study Type
Interventional
Enrollment (Actual)
228
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult male and female adult subjects (age greater than 18 years)
- Referred for cardiac computed tomography angiography (CCTA), myocardial perfusion scintigraphy (MPS), or diagnostic invasive coronary angiography (ICA).
Exclusion Criteria:
- Female patients that identify themselves as pregnant or have a positive pregnancy test prior to cardiac imaging.
- History (present or past) of leukemia or lymphoma.
- History of radiation therapy
- X-ray examination or scintigraphy within the last 72 hours.
- History of coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention)
- Patients undergoing percutaneous coronary intervention at completion of diagnostic left heart catheterization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: CCTA Breast Shields
Within female subset, randomization to wearing bismuth breast shield.
|
Breast shield placement (randomized) among women.
Other Names:
|
|
No Intervention: CCTA No Breast Shields
Within female subset, randomization to wearing no bismuth breast shield (standard of care).
|
|
|
No Intervention: Observational Arm
Non-females undergoing CTA and subjects undergoing cardiac catheterization and nuclear medicine testing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Excess Double-strand DNA Break Foci Per Cell in Peripheral Blood Samples Post-imaging
Time Frame: Change from baseline double strand DNA breaks at 30 minutes post-imaging
|
The amount of excess DNA double-strand break foci per cell after cardiac computed tomographic angiography (CCTA) in female patients with and without breast shields, minus the amount of foci prior to CCTA.
In addition, changes in DNA double-strand breaks from baseline following cardiac testing in the observational arm is being assessed in an observational manner.
|
Change from baseline double strand DNA breaks at 30 minutes post-imaging
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
November 19, 2015
First Submitted That Met QC Criteria
November 30, 2015
First Posted (Estimate)
December 1, 2015
Study Record Updates
Last Update Posted (Actual)
July 11, 2017
Last Update Submitted That Met QC Criteria
June 12, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 362425
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.